Currently out of the existing stock ratings of Ashwani Verma, 117 are a BUY (70.06%), 46 are a HOLD (27.54%), 4 are a SELL (2.4%).

Ashwani Verma

Work Performance Price Targets & Ratings Chart

Analyst Ashwani Verma, currently employed at UBS, carries an average stock price target met ratio of 60.94% that have a potential upside of 23.96% achieved within 170 days.

Ashwani Verma’s has documented 330 price targets and ratings displayed on 27 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 17-Aug-2026.

Wall Street Analyst Ashwani Verma

Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 7/14/2025. The price target of $130 was fulfilled within 1 day with a profit of $3.11 (2.34%) receiving and performance score of 23.36.

Average potential price target upside

of $105.5 (30.62%) on UTHR (UNITED THERAPEUTICS).
of $36.42 (27.13%) on AXSM (AXSOME THERAPEUTICS).
of $30.51 (24.85%) on JAZZ (JAZZ PHARMACEUTICALS PLC).

ITCI Intracellular Th HZNP Horizon Pharma PLC CHRS Coherus BioSciences JAZZ Jazz Pharmaceuticals PLC RPRX Royalty Pharma Plc TEVA Teva Pharma Industries Ltd ADR VTRS Viatris CYTK Cytokinetics KRTX Karuna Therapeutics NBIX Neurocrine Biosciences UTHR United Therapeutics ALKS Alkermes Plc AXSM Axsome Therapeutics RANI Rani Therapeutics Holdings ACAD ACADIA Pharmaceuticals ACLX Arcellx AVDL Avadel Pharmaceuticals PLC BHVN Biohaven Pharmaceutical Holding Co Ltd EXEL Exelixis LEGN Legend Biotech Corp HRMY Harmony Biosciences Holdings BIIB Biogen INCY yte INSM Insmed ALVO Alvotech IT Gartner RCKT Rocket Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Charles Duncan (CANTOR FITZGERALD)